Semaglutide Slashes Inflammation Marker by 37.8%, Potentially Explaining Heart Benefits

Introduction

The groundbreaking SELECT trial established that semaglutide, a popular GLP-1 receptor agonist, significantly reduces the risk of major adverse cardiovascular events (MACEs) in individuals with established atherosclerotic cardiovascular disease (ASCVD) who are overweight or obese but do not have diabetes. While the drug’s cardiovascular benefits are clear, the precise mechanisms behind this protection have remained a subject of intense research. A recent prespecified secondary analysis of the SELECT trial data, published in Circulation, sheds new light on this question by focusing on the role of systemic inflammation, specifically measured by high-sensitivity C-reactive protein (hsCRP).

Key Details

• The analysis examined data from 17,485 participants in the SELECT trial who had baseline hsCRP measurements.
• Semaglutide treatment resulted in a 37.8% placebo-corrected reduction in hsCRP levels by week 104.
• Reductions in hsCRP were observed early, with a 12% decrease at 4 weeks and 19% at 8 weeks, even before participants reached the full 2.4 mg weekly dose and with minimal weight loss.
• Higher baseline hsCRP levels were strongly associated with an increased risk of future cardiovascular events and mortality. Those with hsCRP ≥10 mg/L had approximately double the risk of MACEs compared to those with hsCRP < 2 mg/L.
• Greater weight loss correlated with larger hsCRP reductions, but significant anti-inflammatory effects were also noted in participants with minimal or no weight loss.
• Statistical modeling suggested that changes in hsCRP partially accounted for semaglutide’s cardiovascular benefits, indicating inflammation may contribute to some, but not all, of the observed risk reduction.
• Women showed a proportionally larger decrease in hsCRP compared to men.

Background

Atherosclerosis, the underlying cause of many heart attacks and strokes, is fundamentally an inflammatory process. It involves the buildup of plaques in arteries, which can become unstable and lead to blockages. Systemic inflammation is a key driver of this process, and hsCRP is a widely recognized biomarker reflecting this inflammation. Elevated hsCRP levels have consistently been linked to a higher risk of cardiovascular events and mortality, independent of other traditional risk factors like cholesterol levels.

Obesity is also known to promote a state of chronic, low-grade inflammation. Adipose (fat) tissue can release inflammatory substances, contributing to the overall inflammatory burden in the body. GLP-1 receptor agonists, like semaglutide, are effective in promoting weight loss, and it was hypothesized that their cardiovascular benefits might be partly mediated by reducing this obesity-driven inflammation.

Impact Analysis

This study provides compelling evidence that semaglutide exerts a significant anti-inflammatory effect, as measured by hsCRP. The 37.8% reduction is substantial and occurred rapidly, suggesting that the drug directly impacts inflammatory pathways. Crucially, the observation that hsCRP levels decreased even before significant weight loss or among those with minimal weight loss challenges the notion that inflammation reduction is solely a consequence of weight reduction. This points towards a potential direct anti-inflammatory action of semaglutide itself, possibly through mechanisms independent of adiposity changes.

The finding that higher baseline hsCRP predicts worse outcomes reinforces its value as a prognostic marker. For clinicians, this suggests that measuring hsCRP could help identify patients with established ASCVD and obesity who are at higher residual risk, even if they are on standard treatment. The partial attenuation of semaglutide’s cardiovascular benefit when hsCRP changes were accounted for in statistical models is a key finding. It indicates that while inflammation reduction likely plays a role, other factors, such as direct effects on plaque stability, endothelial function, or metabolic improvements beyond weight loss, also contribute significantly to semaglutide’s cardioprotective effects.

“The present study supports the use of elevated baseline hsCRP as a marker of residual cardiovascular risk and shows that semaglutide is associated with rapid and sustained reductions in hsCRP.”

Broader Context

The rise of obesity and its associated cardiovascular complications has made effective treatments crucial. Semaglutide, initially developed for diabetes, has shown remarkable efficacy in weight management and now, as demonstrated by the SELECT trial, in reducing cardiovascular events in a high-risk population. This new analysis places these benefits within the context of inflammation, a central player in cardiovascular disease pathogenesis. Understanding the interplay between weight loss, inflammation, and cardiovascular outcomes is vital for optimizing treatment strategies.

The study’s findings also highlight the complexity of drug mechanisms. While weight loss is a major effect of semaglutide, attributing its cardiovascular benefits solely to weight reduction is an oversimplification. The drug likely engages multiple pathways, including direct effects on inflammatory signaling, metabolic improvements, and potentially beneficial changes in the gut microbiome or cardiac metabolism, which are areas for future investigation.

Future Outlook

This research opens avenues for further investigation. Future studies could explore the specific molecular pathways through which semaglutide reduces hsCRP, potentially involving direct effects on immune cells or adipose tissue signaling. While hsCRP is a valuable marker, its role as a selection criterion for semaglutide therapy was not established in this analysis. Further research might clarify if patients with high hsCRP levels derive even greater benefit from semaglutide, although the current data suggest broad benefits across different hsCRP levels. The study also underscores the importance of considering inflammation as a therapeutic target in cardiovascular disease management, especially in the context of obesity.

Conclusion

This secondary analysis of the SELECT trial provides significant insights into the mechanisms underlying semaglutide’s cardiovascular benefits. It demonstrates that semaglutide effectively reduces systemic inflammation, as indicated by a substantial decrease in hsCRP levels, an effect that appears partly independent of weight loss and occurs early in treatment. While this anti-inflammatory action likely contributes to the drug's cardioprotective effects, it is probably not the sole mechanism. The study reinforces the prognostic value of hsCRP in identifying patients at high risk and suggests that semaglutide offers a multifaceted approach to cardiovascular risk reduction in individuals with established ASCVD and overweight or obesity.